All News

DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

SGLT2 Inhibitor Protective Effects in Lupus

Jack Cush, MD

Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).

Read Article
dupuytrens

Treatment Options for Dupuytren’s Contracture

Jack Cush, MD

The NEJM reports that in a randomized, controlled, head to head trial, collagenase injections were non-inferior to limited fasciectomy in the treatment of Dupuytren’s contracture.

Read Article
RheumNow Podcast square

Blue Collar Arthritis (10.25.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Pills.JIA_.png

Trends in DMARD Use in Juvenile Arthritis 2001-2022

Jack Cush, MD

Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional DMARD use.

Read Article
106-0674_IMG.JPG

Potential OA Treatment - Chemokine CCL17 Inhibition

MedPage Today

Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.

Read Article
juvDM1.jpg

Long-term Tofacitinib in Juvenile Idiopathic Arthritis

Jack Cush, MD

The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.

Read Article
knee.injx_.ant_.jpg

SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA

Jack Cush, MD

A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA).

Read Article
pregn.outcome.jpg

Predictors of Adverse Pregnancy Outcomes in Lupus

Jack Cush, MD

A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before and at concept

Read Article
Joint.pain.hands.blue

Pain Relief in RA: JAK Better than TNF Inhibitors?

MedPage Today

Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.

Read Article
Treatment Options for Dupuytren’s Contracture The NEJM reports that in a randomized, controlled, head to head trial, collagenase injections were non-inferior to limited fasciectomy in the treatment of Dupuytren’s contracture. https://t.co/HTW9za8a10 https://t.co/gStCic7x2D

Links:

Dr. John Cush RheumNow ( View Tweet)
STAR study shows 102 RA pts in LDA > 3 mos & pred 5 mg/d did equally well with either prednisone taper or changing to hydrocortisone 20 mg/d and taperin HC. At 12 mos both wer able to D/C GC (55% HC vs 47% pred tapering; p=0.4). https://t.co/C6YTGiF0pN

Links:

Dr. John Cush RheumNow ( View Tweet)

Long-term Tofacitinib in Juvenile Idiopathic Arthritis The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study. https://t.co/IKHM6z8iMB https://t.co/O6ig1lTQR4

Links:

Dr. John Cush RheumNow ( View Tweet)
2 yr results from the PRAIRI study - 78 at-risk (for RA) pts Rx w/ placebo or 1000 mg IV RTX + I00 mg methylprednisolone (MP). While 1 yr result showed brief delay in RA development, at 2 yrs there was no benefit for QOL or RA development https://t.co/1CzEQn5zL4 https://t.co/Wvr2kWvDC5

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study compared IV methylprednisolone (IVMP) to oral glucocorticoids (GC) Rx in 419 #GCA pts (>90% vision Sx). 26% Rx w/ IVMP was not superior at survival or visual ac uity than GC, but IVMP was assoc w/ signif more diabetes @1 yr (OR 2.59) https://t.co/pRBA18Fzyw https://t.co/z6Sw5LTtGq

Links:

Dr. John Cush RheumNow ( View Tweet)
#VEXAS can present as atypical &/or refractory #ANCA-associated #vasculitis Consider possibility of VEXAS in cases of AAV ▶️Refractory to multiple treatment ▶️Atypical kidney biopsy 👉🏽https://t.co/1Vewb5n5vZ via @RheumJnl https://t.co/FLov5xaQAA

Links:

Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Turkish retrospective review of 30 axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of ~ 30mo, SEC retention was 90% @12 mos & 81% @24 mos. There was only 1 local tumor recurrence w bladder carcinoma https://t.co/t7tqPtHOff https://t.co/wfAxwEsZLK

Links:

Dr. John Cush RheumNow ( View Tweet)
Alendronate Atypical Fractures Back In Court Reuters reports that a U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck failed to warn that patients taking alendronate for osteoporosis may be at increased the risk of atypical femoral fractures.… https://t.co/DWXsFyzfWs https://t.co/HhROUArYBE
Dr. John Cush RheumNow ( View Tweet)
Biologic (bio-originators) & biosimilar serious Infx rates are low & similar. Retro Study w/ 2+ yrs F/U shows hosp. Infx to be 7% infliximab & 2% etanercept. Similar SIE w/ ETA IR = 11.8 (7.9, 16.8) vs 8.4 (6.9, 10.1) & INFLX SIE IR= 33.4 (27.2, 40.1) vs 29.3 (26.6,… https://t.co/i2rP88ofEP https://t.co/XBW4tLC8YH
Dr. John Cush RheumNow ( View Tweet)
Inadequate Zoster Vaccination in Immunocompromised Patients A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.… https://t.co/EV24CQazex https://t.co/jiTuWQySgs
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 40 papers, 486,465 RA pts & 3,928 incident ILD outcomes shows no signif risk of ILD w/ DMARD use; no ILD risk w/ TOFA or TNFi (Oral Surveillance n=2,911; OR 0.94). MTX use yielded a Lower ILD risk (OR 0.49; 0.32 to 0.76) vs no MTX use. https://t.co/Es8yyEiD8r https://t.co/qOYPkWNi9o

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×